Recombinant Equine Serum Amyloid A1 Protein

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-62533

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP2-62533
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

E. coli

Accession #

P19857

Conjugate

Unconjugated

Applications

ELISA

View all Serum Amyloid A1 Proteins and Enzymes »

Product Specifications

Description

Recombinant horse serum amyloid A.

Source:Equine

Amino Acid Sequence:120 aa recombinant protein produced in a eukaryotic expression system, which includes a proprietary 10 aa tag at the N-terminus, UniProt P19857

Purity

>95%

Predicted Molecular Mass

13.6 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Protein / Peptide Type

Recombinant Protein

Formulation, Preparation and Storage

NBP2-62533
Formulation 0.01 M HCl
Preservative No Preservative
Concentration Lyoph
Reconstitution Reconstitute with 1.0 ml distilled water. Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Gently mix vial after reconstitution.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Store at -20C. Avoid freeze-thaw cycles.

Background: Serum Amyloid A1

The serum amyloid A (SAA) family comprises a number of differentially expressed lipoproteins, acute phase SAA1 and SAA2, the former being a major component in plasma, and constitutive SAA's (C-SAAs). Although the liver is the primary site of synthesis of both SAA types, extrhepatic production has been reported. The in vivo concentrations increase by as much as 1000 fold during inflammation. Several studies have expressed its importance in the diagnosis and monitoring of various diseases. Pathological SAA values are often detected in association with normal CRP concentrations. SAA rises earlier and more sharply than CRP. SAA enhances the binding of HDL's to macrophages and thus helps the delivery of lipid to sites of injury for use in tissue repair. It is thus thought to be an integral part of the disease process. In addition, recent experiments suggest that SAA may play a quot houekeeping quot role in normal human tissues. Elevated levels of SAA over time predispose secondary amyloidosis, extracellular accumulation of amyloid fibrils, derived from a circulating precursor, in various tissues and organs. The most common form of amyloidosis occurs secondary to chronic inflammatory disease, particularly rheumatoid artheritis. Amyloidosis is a heterogeneous group of disorders characterized by extracellular deposition of abnormal protein fibrils, which are derived from different proteins. Almost all patients with amyloidosis have some level of renal disorders. The immunoperoxidase technique has the advantage of being able to detect amyloid in formalin-fixed paraffin embedded tissues and is a very specific method for identifying amyloid fibril proteins. Small and minute amounts of amyloid can be detected with both Amyloid P (ab688) and Amyloid A antibodies, and thus could allow earlier treatment before organ damage has occurred.

Alternate Names

PIG4, SAA1

Gene Symbol

SAA1

UniProt

P19857 (Equine)

Additional Serum Amyloid A1 Products

Product Documents for Recombinant Equine Serum Amyloid A1 Protein

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Recombinant Equine Serum Amyloid A1 Protein

This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.